FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3112524531> ?p ?o ?g. }

• W3112524531 endingPage "6168" @default.
• W3112524531 startingPage "6157" @default.
• W3112524531 abstract "Abstract CD19-directed chimeric antigen receptor (CAR) T-cell treatment has evolved as standard of care (SOC) for multiply relapsed/refractory (R/R) large B-cell lymphoma (LBCL). However, its potential benefit over allogeneic hematopoietic cell transplantation (alloHCT) remains unclear. We compared outcomes with both types of cellular immunotherapy (CI) by intention to treat (ITT). Eligble were all patients with R/R LBCL and institutional tumor board decision recommending SOC CAR T-cell treatment between July 2018 and February 2020, or alloHCT between January 2004 and February 2020. Primary end point was overall survival (OS) from indication. Altogether, 41 and 60 patients for whom CAR T cells and alloHCT were intended, respectively, were included. In both cohorts, virtually all patients had active disease at indication. CI was recommended as part of second-line therapy for 21 alloHCT patients but no CAR T-cell patients. Median OS from indication was 475 days with CAR T cells vs 285 days with alloHCT (P = .88) and 222 days for 39 patients for whom alloHCT beyond second line was recommended (P = .08). Of CAR T-cell and alloHCT patients, 73% and 65%, respectively, proceeded to CI. After CI, 12-month estimates for nonrelapse mortality, relapse incidence, progression-free survival, and OS for CAR T cells vs alloHCT were 3% vs 21% (P = .04), 59% vs 44% (P = .12), 39% vs 33% (P = .97), and 68% vs 54% (P = .32), respectively. In conclusion, CAR T-cell outcomes were not inferior to alloHCT outcomes, whether measured by ITT or from CI administration, supporting strategies preferring CAR T cells over alloHCT as first CI for multiply R/R LBCL." @default.
• W3112524531 created "2020-12-21" @default.
• W3112524531 creator A5017514499 @default.
• W3112524531 creator A5028388949 @default.
• W3112524531 creator A5031568690 @default.
• W3112524531 creator A5032256693 @default.
• W3112524531 creator A5036688322 @default.
• W3112524531 creator A5041230025 @default.
• W3112524531 creator A5041455562 @default.
• W3112524531 creator A5043634148 @default.
• W3112524531 creator A5045699520 @default.
• W3112524531 creator A5050362680 @default.
• W3112524531 creator A5058238162 @default.
• W3112524531 creator A5059935166 @default.
• W3112524531 creator A5065579746 @default.
• W3112524531 creator A5077620734 @default.
• W3112524531 creator A5080397055 @default.
• W3112524531 creator A5085146093 @default.
• W3112524531 creator A5086694792 @default.
• W3112524531 creator A5091381177 @default.
• W3112524531 date "2020-12-11" @default.
• W3112524531 modified "2023-10-16" @default.
• W3112524531 title "CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison" @default.
• W3112524531 cites W1551467549 @default.
• W3112524531 cites W2003327619 @default.
• W3112524531 cites W2038023916 @default.
• W3112524531 cites W2062437906 @default.
• W3112524531 cites W2087137028 @default.
• W3112524531 cites W2097426308 @default.
• W3112524531 cites W2100090512 @default.
• W3112524531 cites W2128812336 @default.
• W3112524531 cites W2136060045 @default.
• W3112524531 cites W2138874270 @default.
• W3112524531 cites W2152197116 @default.
• W3112524531 cites W2179179262 @default.
• W3112524531 cites W2300560420 @default.
• W3112524531 cites W2305142474 @default.
• W3112524531 cites W2556342759 @default.
• W3112524531 cites W2717271878 @default.
• W3112524531 cites W2744261860 @default.
• W3112524531 cites W2773804840 @default.
• W3112524531 cites W2799756006 @default.
• W3112524531 cites W2809013389 @default.
• W3112524531 cites W2889921858 @default.
• W3112524531 cites W2892311750 @default.
• W3112524531 cites W2903062212 @default.
• W3112524531 cites W2903225254 @default.
• W3112524531 cites W2935210822 @default.
• W3112524531 cites W2944689312 @default.
• W3112524531 cites W2948517706 @default.
• W3112524531 cites W2963496214 @default.
• W3112524531 cites W2969216121 @default.
• W3112524531 cites W2974108516 @default.
• W3112524531 cites W2981626013 @default.
• W3112524531 cites W2982584762 @default.
• W3112524531 cites W2994015348 @default.
• W3112524531 cites W2997775719 @default.
• W3112524531 cites W3024551293 @default.
• W3112524531 cites W3024978145 @default.
• W3112524531 cites W3037322433 @default.
• W3112524531 cites W3043369050 @default.
• W3112524531 cites W3090872582 @default.
• W3112524531 doi "https://doi.org/10.1182/bloodadvances.2020003036" @default.
• W3112524531 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7756983" @default.
• W3112524531 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33351108" @default.
• W3112524531 hasPublicationYear "2020" @default.
• W3112524531 type Work @default.
• W3112524531 sameAs 3112524531 @default.
• W3112524531 citedByCount "22" @default.
• W3112524531 countsByYear W31125245312021 @default.
• W3112524531 countsByYear W31125245312022 @default.
• W3112524531 countsByYear W31125245312023 @default.
• W3112524531 crossrefType "journal-article" @default.
• W3112524531 hasAuthorship W3112524531A5017514499 @default.
• W3112524531 hasAuthorship W3112524531A5028388949 @default.
• W3112524531 hasAuthorship W3112524531A5031568690 @default.
• W3112524531 hasAuthorship W3112524531A5032256693 @default.
• W3112524531 hasAuthorship W3112524531A5036688322 @default.
• W3112524531 hasAuthorship W3112524531A5041230025 @default.
• W3112524531 hasAuthorship W3112524531A5041455562 @default.
• W3112524531 hasAuthorship W3112524531A5043634148 @default.
• W3112524531 hasAuthorship W3112524531A5045699520 @default.
• W3112524531 hasAuthorship W3112524531A5050362680 @default.
• W3112524531 hasAuthorship W3112524531A5058238162 @default.
• W3112524531 hasAuthorship W3112524531A5059935166 @default.
• W3112524531 hasAuthorship W3112524531A5065579746 @default.
• W3112524531 hasAuthorship W3112524531A5077620734 @default.
• W3112524531 hasAuthorship W3112524531A5080397055 @default.
• W3112524531 hasAuthorship W3112524531A5085146093 @default.
• W3112524531 hasAuthorship W3112524531A5086694792 @default.
• W3112524531 hasAuthorship W3112524531A5091381177 @default.
• W3112524531 hasBestOaLocation W31125245311 @default.
• W3112524531 hasConcept C109159458 @default.
• W3112524531 hasConcept C121332964 @default.
• W3112524531 hasConcept C121608353 @default.
• W3112524531 hasConcept C126322002 @default.
• W3112524531 hasConcept C141071460 @default.
• W3112524531 hasConcept C142424586 @default.

• next